Key facts
- Ribo Life Science’s last known valuation is $1.2B (Jan 2026).
- It has raised $285.3M; the latest was IPO ($235.4M) in Jan 2026.
- Notable investors include CICC Capital, Kunshan Hi-tech Venture Capital, China Asset Management Company, Springs Capital, Ivyrock Asset Management — 12 tracked in total.
- Status: Publicly Held.
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Ribo Life Science
- ·The full record, as it builds
Funding rounds
No funding rounds for Ribo Life Science are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ribo Life Science
Developer and provider of RNA interference ( RNAi ) technology designed to treat liver diseases. The company's RNA interference ( RNAi ) technology is used to develop nucleic acid therapeutic drugs and related products, enabling healthcare providers to deliver more effective pharmaceuticals to patients.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2007
- Employees
- 278
- Website
- ribolia.com/
- Ownership
- Publicly Held
Ribo Life Science doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ribo Life Science shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ribo Life Science in its N-PORT filings yet. We sweep new filings monthly.